Electric Comb Outperforms Traditional Baldness Treatments in New Study

2026-11-15 general

Boston, Saturday, 14 November 2026.
A novel bioelectronic device achieved nearly 98% hair regrowth in preclinical trials, outperforming leading pharmaceuticals and signaling potential disruption across the multi-billion-dollar global hair loss treatment market.

A Breakthrough in Bioelectronics: The Detangle Comb

Biomedical engineers from Beihang University in Beijing have unveiled ‘Detangle,’ a bioelectronic comb designed to revolutionize hair regrowth treatments [GPT]. Published in Nature Communications on November 3, 2026, the device features electronic teeth with height-differentiated electrodes and integrated drug-loading modules, generating an electric field approximately nine times deeper than conventional external applications [1]. The innovation arrives as the global hair loss treatment market, valued at over $4 billion in 2025, continues to seek alternatives to pharmaceuticals like minoxidil and finasteride, which face compliance and side-effect challenges [GPT].

Preclinical Triumph: Near-Complete Hair Regrowth in Mice

In a 28-day preclinical trial on male mice with testosterone-induced hair loss, the Detangle comb demonstrated remarkable efficacy. Untreated mice regrew only 1% of hair, while electrostimulation alone achieved 40% regrowth. Traditional treatments fared modestly better, with finasteride at 50% and minoxidil at 70%. However, when combined with Detangle’s electrostimulation, the results soared: SRD5A2 siRNA paired with the device achieved 85% regrowth, and VEGFA plasmid paired with it reached 90%. The full Detangle treatment—electrostimulation plus both VEGFA plasmid and SRD5A2 siRNA—delivered a staggering 97.85% hair recovery [1][2]. These outcomes, published in Nature Communications, represent a leap forward in non-invasive hair regrowth technology [1].

Mechanism and Market Potential

The Detangle comb’s electrodes create a directional electric field 2.63 times stronger than aligned electrodes, penetrating nine times deeper into hair follicle regions [2]. This enhanced field drives charged molecules—such as VEGFA plasmid for angiogenesis and SRD5A2 siRNA to inhibit dihydrotestosterone (DHT)—into follicular cells, increasing intracellular uptake efficiency by up to 3.4-fold [2]. The system’s battery-free design and contact-triggered molecular deployment distinguish it from traditional topical treatments, offering a potential advantage in patient compliance [2][GPT]. With androgenetic alopecia affecting over 1 billion people worldwide, the market for such disruptive technology is substantial [1].

From Lab to Market: Challenges and Opportunities

While preclinical results are promising, critical questions remain. The findings are based on mouse models, and human trials have yet to commence [alert! ‘No human trials confirmed as of November 2026’][3]. Previous bioelectronic devices, such as Rise Technology’s hair growth cap developed in 2019, have faced delays in commercialization, with no confirmed release date as of November 2026 [2]. However, the Detangle comb’s simplicity—requiring application once every three days—could accelerate its path to market [2]. Media coverage in outlets like Gizmodo, Medical Xpress, and ZME Science over the past two days underscores the public’s keen interest in this innovation [2]. For investors and medtech companies, the Detangle comb represents a high-potential disruptor in the hair loss treatment sector, though regulatory hurdles and scalability challenges loom large [GPT].

Sources

Bioelectronics Alopecia treatments